Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.
In this study, we have the objective of evaluating the lymphoproliferative response and determining interferon (IFN)-gamma and interleukin (IL)-10 cytokine production in the peripheral blood mononuclear cells (PBMC) of patients with American tegumentary leishmaniasis prior and post 12 months of chemotherapy treatment with meglumine antimoniate compared with the PBMC of noninfected donors. Lymphoproliferation, such as cytokine production, was evaluated through in vitro stimulus with the soluble antigenic fraction from Leishmania (Viannia) braziliensis promastigotes (1.25 microg/ml) and Concanavalin A (2.5 microg/ml). Patients showed a significant lymphoproliferative response prior and post treatment compared with the control group. Similar result, prior to chemotherapy treatment, was observed in IFN-gamma and IL-10 production when patients were compared with the control group. After chemotherapy treatment, PBMC lymphoproliferative response of the patients revealed an increase, whereas patients have shown a decrease in IFN-gamma levels and an increase in IL-10, although without statistical difference. These results may indicate that the patients produced a specific cellular response to the soluble antigenic fraction suggesting that besides Th1 and Th2 dichotomy, immunological regulation mechanisms with the participation of memory T cells and regulatory T cells could be present in the clinical evolution of these patients. This understanding will allow the study and identification of new L. (V.) braziliensis molecules potentially candidates to vaccines.
Reis
Luiza C
LC
Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães-CPqAM/Fiocruz, Recife, PE, Brazil.
Brito
Maria Edilenza F
ME
Souza
Marina A
MA
Medeiros
Angela C R
AC
Silva
Claudio J
CJ
Luna
Carlos F
CF
Pereira
Valéria R A
VR
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D016022:Case-Control Studies; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology*; D007371:Interferon-gamma / Q000032:analysis / Q000276:immunology*; D016753:Interleukin-10 / Q000032:analysis / Q000276:immunology*; D007892:Leishmania braziliensis / Q000276:immunology; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000276:immunology* / Q000469:parasitology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D000953:Antigens, Protozoan; C508609:IL10 protein, human; D009942:Organometallic Compounds; D003208:Concanavalin A; D016753:Interleukin-10; D008536:Meglumine; D000077485:Meglumine Antimoniate; D007371:Interferon-gamma